Literature DB >> 1311715

A human lymphoma cell line with multiple immunoglobulin rearrangements.

H Chang1, H A Messner, X H Wang, C Yee, L Addy, J Meharchand, M D Minden.   

Abstract

The development of a cell culture system efficient in the establishment of lymphoma cell lines has made it possible to dissect basic biological and molecular aspects of lymphoma cells. We have established a lymphoma cell line from a patient with B cell lymphoma. The cell line has a complex karyotype with translocations involving bands 8q24, 14q32, and 18q21. Molecular analysis revealed that the Myc gene was rearranged; we were unable to demonstrate rearrangement of the Bcl-2 gene. Evaluation of the structure of the heavy chain Ig genes revealed that the cell line carried the same rearrangements as the cells from which the cell line was derived. The pattern of rearrangement, however, was unusual in that there were at least four rearranged bands when DNA cut with HindIII was probed with a fragment of the heavy chain joining region. To further characterize the cell line, subclones were derived. Individual subclones had the same pattern of rearrangement as the parent cell line. The results of these studies provide evidence that multiple rearranged Ig genes may be present in a single clone of cells.

Entities:  

Mesh:

Year:  1992        PMID: 1311715      PMCID: PMC442951          DOI: 10.1172/JCI115642

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  38 in total

Review 1.  Somatic mutation in human B-cell tumors.

Authors:  R Levy; S Levy; M L Cleary; W Carroll; S Kon; J Bird; J Sklar
Journal:  Immunol Rev       Date:  1987-04       Impact factor: 12.988

2.  Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas.

Authors:  L M Weiss; R A Warnke; J Sklar; M L Cleary
Journal:  N Engl J Med       Date:  1987-11-05       Impact factor: 91.245

3.  A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia.

Authors:  L Pegoraro; A Palumbo; J Erikson; M Falda; B Giovanazzo; B S Emanuel; G Rovera; P C Nowell; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

4.  Cloning and characterization of different human sequences related to the onc gene (v-myc) of avian myelocytomatosis virus (MC29).

Authors:  R Dalla-Favera; E P Gelmann; S Martinotti; G Franchini; T S Papas; R C Gallo; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

5.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1983-07-01       Impact factor: 3.365

6.  Evolution of B-cell malignancy: pre-B-cell leukemia resulting from MYC activation in a B-cell neoplasm with a rearranged BCL2 gene.

Authors:  C E Gauwerky; F G Haluska; Y Tsujimoto; P C Nowell; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

7.  Lymphoproliferative disorders in cardiac transplant recipients are multiclonal lymphomas.

Authors:  M L Cleary; J Sklar
Journal:  Lancet       Date:  1984-09-01       Impact factor: 79.321

8.  Clustered arrangement of immunoglobulin lambda constant region genes in man.

Authors:  P A Hieter; G F Hollis; S J Korsmeyer; T A Waldmann; P Leder
Journal:  Nature       Date:  1981-12-10       Impact factor: 49.962

9.  Evolution of human immunoglobulin kappa J region genes.

Authors:  P A Hieter; J V Maizel; P Leder
Journal:  J Biol Chem       Date:  1982-02-10       Impact factor: 5.157

10.  Single cell origin of bigenotypic and biphenotypic B cell proliferations in human follicular lymphomas.

Authors:  M L Cleary; N Galili; M Trela; R Levy; J Sklar
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

View more
  1 in total

1.  c-KIT expression enhances the leukemogenic potential of 32D cells.

Authors:  Q Hu; M Trevisan; Y Xu; W Dong; S A Berger; S D Lyman; M D Minden
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.